shRNA and siRNA delivery to the brain

Advanced Drug Delivery Reviews

Volumn 59, Issue 2-3, 2007, Pages 141-152

  Pardridge, William M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Blood brain barrier; Endothelium; Insulin receptor; Monoclonal antibody; RNAi; Transferrin receptor

Indexed keywords

BLOOD; BRAIN; CELL CULTURE; CELL MEMBRANES; IMMUNOLOGY; LIPOSOMES; MONOCLONAL ANTIBODIES; RNA;

BLOOD BRAIN BARRIER (BBB); INSULIN RECEPTOR; NUCLEIC ACID DRUGS; PEGYLATED IMMUNOLIPOSOMES (PIL); RNA INTERFERENCE (RNAI); TRANSFERRIN RECEPTOR;

DRUG DELIVERY;

ANTISENSE OLIGODEOXYNUCLEOTIDE; AVIDIN; BETA GALACTOSIDASE; BIOTIN; BRAIN DERIVED NEUROTROPHIC FACTOR; COMPLEMENTARY RNA; EPIDERMAL GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 2; IMMUNOLIPOSOME; LUCIFERASE; PEPTIDE NUCLEIC ACID; PLASMID DNA; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; TYROSINE 3 MONOOXYGENASE; VASOACTIVE INTESTINAL POLYPEPTIDE;

ANTISENSE THERAPY; BLOOD BRAIN BARRIER; BRAIN CAPILLARY; BRAIN INFARCTION; BRAIN INFARCTION SIZE; DRUG DELIVERY SYSTEM; DRUG FORMULATION; GENETIC ENGINEERING; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; NONVIRAL GENE THERAPY; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REVIEW; RHESUS MONKEY; RNA INTERFERENCE; SIMIAN VIRUS 40; STROKE; THERAPY EFFECT; TRANSGENE; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANIMALS; BRAIN; CARRIER PROTEINS; DRUG DELIVERY SYSTEMS; HUMANS; PLASMIDS; REPRODUCIBILITY OF RESULTS; RNA, SMALL INTERFERING;

EID: 34248679586     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.addr.2007.03.008     Document Type: Review

References (54)

1. McManus M.T., and Sharp P.A. Gene silencing in mammals by small interfering RNAs. Nat. Rev. Genet. 3 (2002) 737-747
2. Brightman M.W., Reese T.S., and Feder N. Assessment with the electron microscope of the permeability to peroxidase of cerebral endothelium and epithelium in mice and sharks. Capillary Permeability (1970), Munksgaard, Copenhagen 463
3. Pardridge W.M. Brain Drug Targeting; the Future of Brain Drug Development (2001), Cambridge University Press, Cambridge, United Kingdom 1-370
4. Pardridge W.M. The blood-brain barrier: bottleneck in brain drug development. NeuroRx 2 (2005) 3-14
5. Zhang Y., and Pardridge W.M. Rapid transferrin efflux from brain to blood across the blood-brain barrier. J. Neurochem. 76 (2001) 1597-1600
6. Lee H.J., Engelhardt B., Lesley J., Bickel U., and Pardridge W.M. Targeting rat anti-mouse transferrin receptor monoclonal antibodies through blood-brain barrier in mouse. J. Pharmacol. Exp. Ther. 292 (2000) 1048-1052
7. Pardridge W.M., Buciak J.L., and Friden P.M. Selective transport of an anti-transferrin receptor antibody through the blood-brain barrier in vivo. J. Pharmacol. Exp. Ther. 259 (1991) 66-70
8. Pardridge W.M., Kang Y.S., Buciak J.L., and Yang J. Human insulin receptor monoclonal antibody undergoes high affinity binding to human brain capillaries in vitro and rapid transcytosis through the blood-brain barrier in vivo in the primate. Pharm. Res. 12 (1995) 807-816
9. Coloma M.J., et al. Transport across the primate blood-brain barrier of a genetically engineered chimeric monoclonal antibody to the human insulin receptor. Pharm. Res. 17 (2000) 266-274
10. Wu D., and Pardridge W.M. Central nervous system pharmacologic effect in conscious rats after intravenous injection of a biotinylated vasoactive intestinal peptide analog coupled to a blood-brain barrier drug delivery system. J. Pharmacol. Exp. Ther. 279 (1996) 77-83
11. Wu D., and Pardridge W.M. Neuroprotection with noninvasive neurotrophin delivery to the brain. Proc. Natl. Acad. Sci. U. S. A. 96 (1999) 254-259
12. Zhang Y., and Pardridge W.M. Conjugation of brain-derived neurotrophic factor to a blood-brain barrier drug targeting system enables neuroprotection in regional brain ischemia following intravenous injection of the neurotrophin. Brain Res. 889 (2001) 49-56
13. Zhang Y., and Pardridge W.M. Neuroprotection in transient focal brain ischemia after delayed intravenous administration of brain-derived neurotrophic factor conjugated to a blood-brain barrier drug targeting system. Stroke 32 (2001) 1378-1384
14. Song B.W., Vinters H.V., Wu D., and Pardridge W.M. Enhanced neuroprotective effects of basic fibroblast growth factor in regional brain ischemia after conjugation to a blood-brain barrier delivery vector. J. Pharmacol. Exp. Ther. 301 (2002) 605-610
15. Kurihara A., and Pardridge W.M. Imaging brain tumors by targeting peptide radiopharmaceuticals through the blood-brain barrier. Cancer Res. 59 (1999) 6159-6163
16. Zhang Y., and Pardridge W.M. Delivery of beta-galactosidase to mouse brain via the blood-brain barrier transferrin receptor. J. Pharmacol. Exp. Ther. 313 (2005) 1075-1081
17. Shi N., and Pardridge W.M. Noninvasive gene targeting to the brain. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 7567-7572
18. Shah N., Zhang S., Harada S., Smith R.M., and Jarett L. Electron microscopic visualization of insulin translocation into the cytoplasm and nuclei of intact H35 hepatoma cells using covalently linked Nanogold-insulin. Endocrinology 136 (1995) 2825-2835
19. Zhang Y., Jeong Lee H., Boado R.J., and Pardridge W.M. Receptor-mediated delivery of an antisense gene to human brain cancer cells. J. Gene Med. 4 (2002) 183-194
20. Zhang Y., Calon F., Zhu C., Boado R.J., and Pardridge W.M. Intravenous nonviral gene therapy causes normalization of striatal tyrosine hydroxylase and reversal of motor impairment in experimental Parkinsonism. Hum. Gene Ther. 14 (2003) 1-12
21. Pardridge W.M. Gene targeting in vivo with pegylated immunoliposomes. Methods Enzymol. 373 (2003) 507-528
22. Norman J., et al. Liposome-mediated, nonviral gene transfer induces a systemic inflammatory response which can exacerbate pre-existing inflammation. Gene Ther. 7 (2000) 1425-1430
23. Loisel S., Le Gall C., Doucet L., Ferec C., and Floch V. Contribution of plasmid DNA to hepatotoxicity after systemic administration of lipoplexes. Hum. Gene Ther. 12 (2001) 685-696
24. Elouahabi A., et al. Free cationic liposomes inhibit the inflammatory response to cationic lipid-DNA complex injected intravenously and enhance its transfection efficiency. Molec. Ther. 7 (2003) 81-88
25. Shi N., Zhang Y., Zhu C., Boado R.J., and Pardridge W.M. Brain-specific expression of an exogenous gene after i.v. administration. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 12754-12759
26. Zhu C., Zhang Y., and Pardridge W.M. Widespread expression of an exogenous gene in the eye after intravenous administration. Invest. Ophthalmol. Vis. Sci. 43 (2002) 3075-3080
27. Zhang Y., Schlachetzki F., Li J.Y., Boado R.J., and Pardridge W.M. Organ-specific gene expression in the Rhesus monkey eye following intravenous non-viral gene transfer. Mol. Vis. 9 (2003) 465-472
28. Zhang Y., Schlachetzki F., and Pardridge W.M. Global non-viral gene transfer to the primate brain following intravenous administration. Molec. Ther. 7 (2003) 11-18
29. Chu C., Zhang Y., Boado R.J., and Pardridge W.M. Decline in exogenous gene expression in primate brain following intravenous administration is due to plasmid degradation. Pharm. Res. 23 (2006) 1586-1599
30. Zhang Y., Schlachetzki F., Zhang Y.F., Boado R.J., and Pardridge W.M. Normalization of striatal tyrosine hydroxylase and reversal of motor impairment in experimental parkinsonism with intravenous nonviral gene therapy and a brain-specific promoter. Hum. Gene Ther. 15 (2004) 339-350
31. Naeser P. Insulin receptors in human ocular tissues. Immunohistochemical demonstration in normal and diabetic eyes. Ups. J. Med. Sci. 102 (1997) 35-40
32. Shi N., Boado R.J., and Pardridge W.M. Receptor-mediated gene targeting to tissues in vivo following intravenous administration of pegylated immunoliposomes. Pharm. Res. 18 (2001) 1091-1095
33. Zhang Y., Boado R.J., and Pardridge W.M. In vivo knockdown of gene expression in brain cancer with intravenous RNAi in adult rats. J. Gene Med. 5 (2003) 1039-1045
34. Kuan C.T., Wikstrand C.J., and Bigner D.D. EGF mutant receptor vIII as a molecular target in cancer therapy. Endocr. Relat. Cancer 8 (2001) 83-96
35. Nicholson R.I., Gee J.M., and Harper M.E. EGFR and cancer prognosis. Eur. J. Cancer 37 Suppl 4 (2001) S9-S15
36. Abe T., et al. PTEN decreases in vivo vascularization of experimental gliomas in spite of proangiogenic stimuli. Cancer Res. 63 (2003) 2300-2305
37. Zhang Y., et al. Intravenous RNA interference gene therapy targeting the human epidermal growth factor receptor prolongs survival in intracranial brain cancer. Clin. Cancer Res. 10 (2004) 3667-3677
38. Zhang Y., Zhu C., and Pardridge W.M. Antisense gene therapy of brain cancer with an artificial virus gene delivery system. Molec. Ther. 6 (2002) 67-72
39. Wu C.H., Wilson J.M., and Wu G.Y. Targeting genes: delivery and persistent expression of a foreign gene driven by mammalian regulatory elements in vivo. J. Biol. Chem. 264 (1989) 16985-16987
40. Kwoh D.Y., et al. Stabilization of poly-l-lysine/DNA polyplexes for in vivo gene delivery to the liver. Biochim. Biophys. Acta 1444 (1999) 171-190
41. Vehaskari V.M., Chang C.T., Stevens J.K., and Robson A.M. The effects of polycations on vascular permeability in the rat. A proposed role for charge sites. J. Clin. Invest. 73 (1984) 1053-1061
42. Green N.M. Avidin. Adv. Protein Chem. 29 (1975) 85-133
43. Suzuki T., et al. Imaging endogenous gene expression in brain cancer in vivo with 111In-peptide nucleic acid antisense radiopharmaceuticals and brain drug-targeting technology. J. Nucl. Med. 45 (2004) 1766-1775
44. Tidd D.M., and Warenius H.M. Partial protection of oncogene, anti-sense oligodeoxynucleotides against serum nuclease degradation using terminal methylphosphonate groups. Br. J. Cancer 60 (1989) 343-350
45. Marcus-Sekura C.J., Woerner A.M., Shinozuka K., Zon G., and Quinnan Jr. G.V. Comparative inhibition of chloramphenicol acetyltransferase gene expression by antisense oligonucleotide analogues having alkyl phosphotriester, methylphosphonate and phosphorothioate linkages. Nucleic Acids Res. 15 (1987) 5749-5763
46. Ho P.T., Ishiguro K., Wickstrom E., and Sartorelli A.C. Non-sequence-specific inhibition of transferrin receptor expression in HL-60 leukemia cells by phosphorothioate oligodeoxynucleotides. Antisense Res. Dev. 1 (1991) 329-342
47. Stein C.A., and Cheng Y.C. Antisense oligonucleotides as therapeutic agents-is the bullet really magical?. Science 261 (1993) 1004-1012
48. Cossum P.A., et al. Disposition of the 14C-labeled phosphorothioate oligonucleotide ISIS 2105 after intravenous administration to rats. J. Pharmacol. Exp. Ther. 267 (1993) 1181-1190
49. Wu D., Boado R.J., and Pardridge W.M. Pharmacokinetics and blood-brain barrier transport of [3H]-biotinylated phosphorothioate oligodeoxynucleotide conjugated to a vector-mediated drug delivery system. J. Pharmacol. Exp. Ther. 276 (1996) 206-211
50. Garner P., Sherry B., Moilanen S., and Huang Y. In vitro stability of alpha-helical peptide nucleic acids (alphaPNAs). Bioorg. Med. Chem. Lett. 11 (2001) 2315-2317
51. Pardridge W.M., Boado R.J., and Kang Y.S. Vector-mediated delivery of a polyamide ("peptide") nucleic acid analogue through the blood-brain barrier in vivo. Proc. Natl. Acad. Sci. U. S. A. 92 (1995) 5592-5596
52. Chiu Y.L., and Rana T.M. RNAi in human cells: basic structural and functional features of small interfering RNA. Mol. Cell 10 (2002) 549-561
53. Penichet M.L., Kang Y.S., Pardridge W.M., Morrison S.L., and Shin S.U. An Anti-transferrin receptor antibody-avidin fusion protein serves as a delivery vehicle for effective brain targeting in an animal model. Initial applications in antisense drug delivery to the brain. J. Immunol. 163 (1999) 4421-4426
54. Zhu C., et al. Organ-specific expression of the lacZ gene controlled by the opsin promoter after intravenous gene administration in adult mice. J. Gene Med. 6 (2004) 906-912